BTX - BTX STOCK NEWS

Brooklyn ImmunoTherapeutics (BTX) announced the appointment of Dr. Michael Andreeff to its Scientific Advisory Board, effective May 21, 2021. Dr. Andreeff, a leading expert in leukemia treatment and molecular hematology at MD Anderson Cancer Center, brings extensive experience in developing therapies for blood disorders. His expertise is anticipated to enhance Brooklyn's gene editing and cell therapy initiatives, especially following the company’s recent licensing agreement for gene editing technology. Brooklyn is currently advancing its IRX-2 program for head and neck cancer, demonstrating promise in clinical trials.

Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced a conference call scheduled for May 25, 2021, at 4:30 p.m. ET. Participants must pre-register to receive the dial-in information. The call will address the company's exploration of cytokine and gene editing therapies for cancer and blood disorders. The lead program, IRX-2, is undergoing a Phase 2A trial, showing promising survival benefits for head and neck cancer patients. The company aims to advance treatments through newly acquired gene editing licenses.

Brooklyn ImmunoTherapeutics (BTX) has announced a publication in Breast Cancer Research showcasing the effectiveness of multiplex immunofluorescence (mIF) in assessing immunological activity of IRX-2 in early-stage breast cancer. This methodology offers improved estimates of treatment-related effects compared to conventional methods. IRX-2, a cytokine-based therapy, has shown promise in increasing immune cell infiltration, particularly when combined with PD-L1-targeted therapies. Brooklyn has launched a Phase 2 trial for IRX-2 in triple-negative breast cancer, with approximately 30 patients expected to participate.

Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced the appointment of Dr. Erich Mohr to its Board of Directors, effective May 7, 2021. Dr. Mohr brings a wealth of experience from leading life sciences firms, focusing on creating value in board and executive roles. He expressed enthusiasm for joining Brooklyn at a pivotal growth stage, particularly due to the promising clinical trials of IRX-2, a cytokine-based treatment for cancer. Additionally, the company has acquired advanced gene editing technology, enhancing its capabilities in oncology and blood disorders.

Brooklyn ImmunoTherapeutics (BTX) has secured an exclusive license for mRNA gene editing technologies from Factor Bioscience and Novellus Therapeutics. This acquisition enables Brooklyn to utilize advanced gene editing and cell therapies, seen as high-efficiency and non-immunogenic. The licensed platform supports both allogeneic and autologous cells, facilitating the development of therapies for various disorders, including sickle cell anemia and tumors. Brooklyn aims to reach the IND stage for at least one indication by 2024, transitioning into a multi-product pipeline.

Brooklyn ImmunoTherapeutics (NYSE American: BTX) appointed Dr. Matthew During to its Scientific Advisory Board on April 26, 2021. Dr. During, a Harvard, MIT, and Yale trained neuroscientist, has extensive experience in gene therapy and has published over 250 scientific articles. His expertise will bolster the development of Brooklyn's lead therapy, IRX-2, which is currently in clinical trials for head and neck cancer and shows overall survival benefits. The company also aims to advance gene editing and cell therapies through collaborations with Factor Bioscience/Novellus.

Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced the grant of two stock options to Dr. Federoff on April 16, 2021. The Time-Based Option covers 2,627,915 shares, with a structured vesting schedule extending to April 2025. The Milestone Option for 597,253 shares will fully vest upon FDA concurrence for a proposed investigational new drug application. Both options are employment inducement grants outside of the company's equity compensation plans. Brooklyn is advancing cytokine-based therapies and is studying IRX-2 in head and neck cancer with promising phase 2A trial results.

Brooklyn ImmunoTherapeutics (NYSE American: BTX) has invested $1 million towards acquiring a license for Factor Bioscience’s and Novellus’ mRNA Gene Editing and Cell Therapies technology. This investment extends the option exercise period for a related license agreement until May 21, 2021. If successful, the agreement could enable Brooklyn to use patented mRNA-based gene editing techniques for treating various cancers and genetic disorders. Additionally, if the agreement is not made by the deadline, Brooklyn will receive a reimbursement of the $1 million payment.

Brooklyn ImmunoTherapeutics (BTX) has appointed Dennis H. Langer, M.D., J.D. as an independent Director, effective May 1, 2021. Dr. Langer brings extensive experience in biotechnology and pharmaceuticals, previously serving as CEO of Neose Technologies and various leadership roles at Dr. Reddy's and GlaxoSmithKline. His appointment is expected to enhance the company's focus on its clinical-stage therapy, IRX-2, which shows promise in head and neck cancer. Moreover, Brooklyn aims to explore innovative technologies in gene editing and cell therapy, further solidifying its position in cancer treatment.